You are here

US top court rejects Helsinn over anti-nausea drug patent in win for Teva

[WASHINGTON] The US Supreme Court on Tuesday refused to revive Swiss drug company Helsinn Healthcare SA's patent on lucrative anti-nausea drug Aloxi in a victory for Teva Pharmaceutical Industries, which launched a generic version of it last year.

The nine justices unanimously upheld a lower court ruling that had canceled Helsinn's patent on Aloxi for violating a provision in US patent law that forbids sales of an invention before applying for a patent. Teva began selling its generic version of the drug in March 2018 after convincing the lower court to invalidate the patent.

REUTERS

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes